Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
15.37
-0.39 (-2.47%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Inhibrx Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Inhibrx Biosciences.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for INBX is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jul 23, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 23, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $27 | Buy | Reiterates | $27 | +75.67% | Nov 20, 2023 |
| JMP Securities | JMP Securities | Buy Maintains $35 → $27 | Buy | Maintains | $35 → $27 | +75.67% | Aug 23, 2023 |
| JMP Securities | JMP Securities | Buy Reiterates $35 | Buy | Reiterates | $35 | +127.72% | May 10, 2023 |
Financial Forecast
Revenue This Year
102.00K
from 1.63M
Decreased by -93.76%
Revenue Next Year
n/a
from 102.00K
EPS This Year
104.08
EPS Next Year
-11.25
from 104.08
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 105,000 | n/a |
| Avg | 102,000 | n/a |
| Low | 98,000 | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | -93.6% | - |
| Avg | -93.8% | - |
| Low | -94.0% | - |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | 122.41 | -9.05 |
| Avg | 104.08 | -11.25 |
| Low | 85.75 | -13.17 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.